1411 related articles for article (PubMed ID: 32983110)
1. Pre-transplant HLA Antibodies and Delayed Graft Function in the Current Era of Kidney Transplantation.
Morath C; Döhler B; Kälble F; Pego da Silva L; Echterdiek F; Schwenger V; Živčić-Ćosić S; Katalinić N; Kuypers D; Benöhr P; Haubitz M; Ziemann M; Nitschke M; Emmerich F; Pisarski P; Karakizlis H; Weimer R; Ruhenstroth A; Scherer S; Tran TH; Mehrabi A; Zeier M; Süsal C
Front Immunol; 2020; 11():1886. PubMed ID: 32983110
[TBL] [Abstract][Full Text] [Related]
2. Differential Impact of Delayed Graft Function in Deceased Donor Renal Transplant Recipients With and Without Donor-specific HLA-antibodies.
Haller J; Wehmeier C; Hönger G; Hirt-Minkowski P; Gürke L; Wolff T; Steiger J; Amico P; Dickenmann M; Schaub S
Transplantation; 2019 Sep; 103(9):e273-e280. PubMed ID: 31205266
[TBL] [Abstract][Full Text] [Related]
3. Pre-transplant donor-specific anti-human leukocyte antigen antibodies are associated with high risk of delayed graft function after renal transplantation.
Peräsaari JP; Kyllönen LE; Salmela KT; Merenmies JM
Nephrol Dial Transplant; 2016 Apr; 31(4):672-8. PubMed ID: 26614272
[TBL] [Abstract][Full Text] [Related]
4. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
[TBL] [Abstract][Full Text] [Related]
6. A paired kidney analysis on the impact of pre-transplant anti-HLA antibodies on graft survival.
Michielsen LA; Wisse BW; Kamburova EG; Verhaar MC; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JF; Hepkema BG; Lambeck AJ; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens M; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KA; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma A; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG; van Zuilen AD
Nephrol Dial Transplant; 2019 Jun; 34(6):1056-1063. PubMed ID: 30365008
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
8. Delayed Graft Function, Predictive Factors, and 7-Year Outcome of Deceased Donor Kidney Transplant Recipients With Different Immunologic Profiles.
Quintella AHDS; Lasmar MF; Fabreti-Oliveira RA; Nascimento E
Transplant Proc; 2018 Apr; 50(3):737-742. PubMed ID: 29661426
[TBL] [Abstract][Full Text] [Related]
9. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation.
DeVos JM; Gaber AO; Knight RJ; Land GA; Suki WN; Gaber LW; Patel SJ
Kidney Int; 2012 Sep; 82(5):598-604. PubMed ID: 22622504
[TBL] [Abstract][Full Text] [Related]
10. HLA Class II Antibodies at the Time of Kidney Transplantation and Cardiovascular Outcome: A Retrospective Cohort Study.
Malfait T; Emonds MP; Daniëls L; Nagler EV; Van Biesen W; Van Laecke S
Transplantation; 2020 Apr; 104(4):823-834. PubMed ID: 31369517
[TBL] [Abstract][Full Text] [Related]
11. Association Between Delayed Graft Function and Graft Loss in Donation After Cardiac Death Kidney Transplants-A Paired Kidney Registry Analysis.
Lim WH; McDonald SP; Russ GR; Chapman JR; Ma MK; Pleass H; Jaques B; Wong G
Transplantation; 2017 Jun; 101(6):1139-1143. PubMed ID: 28538652
[TBL] [Abstract][Full Text] [Related]
12. Peri-operative third party red blood cell transfusion in renal transplantation and the risk of antibody-mediated rejection and graft loss.
Fidler S; Swaminathan R; Lim W; Ferrari P; Witt C; Christiansen FT; D'Orsogna LJ; Irish AB
Transpl Immunol; 2013 Dec; 29(1-4):22-7. PubMed ID: 24090807
[TBL] [Abstract][Full Text] [Related]
13. The Utility of Donor-specific Antibody Monitoring and the Role of Kidney Biopsy in Simultaneous Liver and Kidney Recipients With De Novo Donor-specific Antibodies.
Parajuli S; Aziz F; Blazel J; Muth BL; Garg N; Mohamed M; Rice J; Mezrich JD; Hidalgo LG; Mandelbrot D
Transplantation; 2021 Jul; 105(7):1548-1555. PubMed ID: 32732618
[TBL] [Abstract][Full Text] [Related]
14. Early De Novo Donor Specific Antibody Involvement in Delayed Graft Function After Kidney Transplantation: A Report of 2 Cases.
Zhu L; Chen G; Zhang W; Guo H; Lin Z; Du D; Chen S; Shi H; Liu S; Chen Z
Clin Transpl; 2014; ():231-4. PubMed ID: 26281150
[TBL] [Abstract][Full Text] [Related]
15. Delayed graft function after renal transplantation: an unresolved problem.
Gavela Martínez E; Pallardó Mateu LM; Sancho Calabuig A; Beltrán Catalán S; Kanter Berga J; Ávila Bernabeu AI; Crespo Albiach J
Transplant Proc; 2011; 43(6):2171-3. PubMed ID: 21839224
[TBL] [Abstract][Full Text] [Related]
16. Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death.
Fidler SJ; Irish AB; Lim W; Ferrari P; Witt CS; Christiansen FT
Transpl Immunol; 2013 Jun; 28(4):148-53. PubMed ID: 23665534
[TBL] [Abstract][Full Text] [Related]
17. Risk factors and consequences of delayed graft function.
Ounissi M; Cherif M; Abdallah TB; Bacha M; Hedri H; Abderrahim E; Goucha R; Kheder A; Slama RB; Derouiche A; Chebil M; Bardi R; Sfar I; Gorgi Y
Saudi J Kidney Dis Transpl; 2013 Mar; 24(2):243-6. PubMed ID: 23538345
[TBL] [Abstract][Full Text] [Related]
18. Predictors and outcomes of delayed graft function after living-donor kidney transplantation.
Redfield RR; Scalea JR; Zens TJ; Muth B; Kaufman DB; Djamali A; Astor BC; Mohamed M
Transpl Int; 2016 Jan; 29(1):81-7. PubMed ID: 26432507
[TBL] [Abstract][Full Text] [Related]
19. Impact of Donor Specific HLA Antibody Monitoring After Kidney Transplantation.
Rao S; Ghanta M; Lee IJ; Gillespie A; Parekh HK; Geier SS; Zeng X; Karachristos A; Lau KN; Karhadkar S; Di Carlo A; Sifontis NM; Constantinescu S
Clin Transpl; 2014; ():143-51. PubMed ID: 26281139
[TBL] [Abstract][Full Text] [Related]
20. The 37-year kidney transplantation experience at Siriraj Hospital.
Premasathian N; Vongwiwatana A; Taweemonkongsap T; Amornvesukit T; Limsrichamrern S; Jitpraphai S; Kositamongkol P; Mahawithitwong P; Sritippayawan S; Chanchairujira T; Nualyong C; Vareesangthip K; Vasuvattakul S; Sirivatanauksorn Y
Clin Transpl; 2010; ():141-8. PubMed ID: 21696037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
